Patient selection for immunotherapy in head and neck cancer - Authors' reply

Lancet Oncol. 2021 Jul;22(7):e291-e292. doi: 10.1016/S1470-2045(21)00339-9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Head and Neck Neoplasms* / therapy
  • Humans
  • Immunologic Factors
  • Immunotherapy / adverse effects
  • Patient Selection

Substances

  • Immunologic Factors